Livtencity Tablet, Coated
NDC Package 64764-800-28
Package Information
Livtencity (maribavir) tablets is lIVTENCITY is indicated for the treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet [see Use in Specific Populations (8.4), Clinical Studies (14)]. This formulation utilizes a tablet, coated delivery system. Marketed by Takeda Pharmaceuticals America, Inc., this product is identified by NDC 64764-800 and is authorized under FDA application NDA215596.
Identification & Billing
- RxCUI: 2586073 - maribavir 200 MG Oral Tablet
- RxCUI: 2586079 - LIVTENCITY 200 MG Oral Tablet
- RxCUI: 2586079 - maribavir 200 MG Oral Tablet [Livtencity]
- RxCUI: 2586079 - Livtencity 200 MG Oral Tablet
Clinical Specifications
- Breast Cancer Resistance Protein Inhibitors - [MoA] (Mechanism of Action)
- Cytochrome P450 3A4 Inhibitors - [MoA] (Mechanism of Action)
- Cytomegalovirus pUL97 Kinase Inhibitor - [EPC] (Established Pharmacologic Class)
- Cytomegalovirus pUL97 Kinase Inhibitors - [MoA] (Mechanism of Action)
- P-Glycoprotein Inhibitors - [MoA] (Mechanism of Action)
Regulatory & Marketing
Hierarchy Structure
- 64764 - Takeda Pharmaceuticals America, Inc.
- 64764-800 - Livtencity
- 64764-800-28 - 1 BOTTLE in 1 CARTON / 28 TABLET, COATED in 1 BOTTLE
- 64764-800 - Livtencity
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (64764-800). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 64764-800-28 identifies a specific commercial package of 1 bottle in 1 carton / 28 tablet, coated in 1 bottle of Livtencity, a human prescription drug labeled by Takeda Pharmaceuticals America, Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 1 billable units per package. This tablet, coated is formulated for oral use and contains maribavir as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Takeda Pharmaceuticals America, Inc. on November 23, 2021. The current certification is valid through December 31, 2027.
How is this Takeda Pharmaceuticals America, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 64764080028. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.
